|Articles|September 15, 2002
- BioPharm International-09-01-2002
- Volume 15
- Issue 9
Security in the Corporate Homeland
Author(s)Joseph F. Noferi, Esq.
by Joseph F. Noferi, Chimeric Therapies, Inc.
Advertisement
Articles in this issue
over 23 years ago
Reexamining the Set It and Forget It Approachover 23 years ago
Integrating New Technology into Blood Plasma Fractionationover 23 years ago
Attack Mounts on Pharmaceutical Pricesover 23 years ago
If a Tree Fell in the ForestNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
3
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5
